论文部分内容阅读
目的观察哒嗪酮类新衍生物Ｙ９０９的强心作用并研究其药理作用机制。方法采用豚鼠离体左右心房和心脏制备灌注给药及心肌磷酸二酯酶（ＰＤＥ）活性测定法。结果Ｙ９０９显著增强豚鼠离体左心房和心脏的收缩力且呈剂量依赖性，其作用强度略低于米利农（Ｍｉｌ），略高于咪苯甲嗪酮（ＣＩ９３０），但均无统计学意义；不显著加快离体右心房和心脏的收缩频率并有提高离体心脏冠脉流量的作用；其正性肌力作用不被肾上腺素受体拮抗剂所阻断；对心肌ＰＤＥ活性的抑制作用显著低于Ｍｉｌ，且与其较强的正性肌力作用不平行。结论Ｙ９０９有较强的强心作用且不增加心率，作用强度接近ＣＩ９３０和Ｍｉｌ，作用机制可能同于ＣＩ９３０而不同于Ｍｉｌ，值得进一步研究。
Objective To observe the cardiotoxic effect of a new derivative of pyridazinone Y909 and study its pharmacological mechanism. Methods Perfusion of guinea pig isolated atrial and cardiac preparations and cardiac phosphodiesterase (PDE) activity assay were performed. Results Y909 significantly enhanced contractile force of isolated left atrium and heart in a dose-dependent manner in guinea pigs, which was slightly lower than that of Milrinone and slightly higher than that of imidacitrazone (CI930), but no significant difference was found ; Did not significantly accelerate the contraction of the right atrium and heart in vitro and increased the coronary flow in isolated hearts; its inotropic effect was not blocked by adrenergic receptor antagonists; its inhibitory effect on the activity of PDE Significantly lower than Mil, and with its strong positive inotropic effect is not parallel. Conclusion Y909 has a stronger cardiac function without increasing heart rate, and the intensity of action is close to that of CI930 and Mil. The mechanism may be similar to CI930 but different from Mil, which deserves further study.